Last updated: 2026-09-09 08:42:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Lite Strategy, Inc. (LITS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.12, with a market capitalization of $38.79M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.69 to $3.23. This page covers its latest market performance, valuation, price trends and company information.
$38.79M | |
$1.10 | |
$3.23 | |
$0.69 | |
$1.10 | |
2.21K | |
252.44K | |
-- | |
$3.23 | |
$0.69 | |
-- | |
-- |
Lite Strategy, Inc. (LITS) is trading at $1.12 in pre-market trading as of 2026-09-09 08:40:00, up 2.18% ($0.02) from the previous close of $1.10
Pre-market trading shows how investors are pricing LITS before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Lite Strategy, Inc. (LITS) moved from $0.98 to $1.12, representing a gain of 14.65% ($0.14).
The stock traded between $0.96 and $1.15 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 471.03 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 17.1%
LITS is currently trading at $1.12, placing it 17.1% of the way from its 52-week low of $0.69 to its 52-week high of $3.23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lite Strategy, Inc. (LITS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.